More scrutiny for value-based CAR T models

A letter from Rep. Elijah Cummings (D-Md.) to Office of Management and Budget Director Mick Mulvaney on Wednesday has increased concerns that biopharmas could face greater scrutiny when negotiating value-based pricing arrangements with CMS.

Cummings cited a conflict of interest between the office's associate director, Joseph Grogan, and CMS negotiations of a proposed demonstration project by Novartis AG (NYSE:NVS; SIX:NOVN) for CAR T therapy Kymriah tisagenlecleucel. Grogan was previously an employee of Gilead Sciences Inc. (NASDAQ:GILD), which also develops CAR T therapies...